Search

Your search keyword '"Filomia, R."' showing total 120 results

Search Constraints

Start Over You searched for: Author "Filomia, R." Remove constraint Author: "Filomia, R."
120 results on '"Filomia, R."'

Search Results

1. T.07.7: CHARACTERISTICS AND MANAGEMENT OF HEPATOCELLULAR CARCINOMA (HCC) IN SICILY: FIRST RESULTS OF THE HCC SICILY MULTIDISCIPLINARY NETWORK

2. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

3. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

4. A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort

5. Bone fragility and fracture risk assessment in metabolic disfunction-associated steatotic liver disease.

6. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

7. Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort

9. De-novo occurrence of portal vein thrombosis in patients with HCV-related cirrhosis after sustained virological response: medium to long term observations from the ongoing PITER cohort

10. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort

11. Liver disease is highly prevalent in patients with hereditary transthyretin-related amyloidosis.

14. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

15. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

16. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

17. Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

18. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

19. Corrigendum to 'Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV' [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

20. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study

21. The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated HCV virus infection: An interim analysis in the PITER cohort

22. Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: a prospective analysis in the PITER cohort

23. Multifactor risk evaluation in patients who have eradicated HCV infection: an interim analysis in the PITER cohort

24. IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: a multicenter prospective trial in Italy

25. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

26. HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study

30. Efficacy of early empiric antibiotic treatment and its impact on short-term mortality in cirrhotic patients with subsequent identification of the infecting bacteria

32. Efficacy and safety of 12-week DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort

33. Clinical characterization and economic impact evaluation of anti-HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER)

35. THU-397 - Multifactor risk evaluation in patients who have eradicated HCV infection: an interim analysis in the PITER cohort

36. PS-152 - IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: a multicenter prospective trial in Italy

37. IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: A multicenter prospective trial in Italy

39. Clinical outcome in hospitalized cirrhotic patients with bacterial infections treated with empirical or antibiogram-guided therapy

40. HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study

43. HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study

44. Steatosis in patients with HCV chronic liver disease: Baseline results from patients enrolled in the PITER cohort study

45. Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography

46. SAT-267 - Efficacy and safety of 12-week DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort

47. FRI-280 - Clinical characterization and economic impact evaluation of anti-HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER)

49. FRI-181 - HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study

Catalog

Books, media, physical & digital resources